Unicycive Therapeutics Inc

Unicycive Therapeutics Inc(UNCY)の株式分析

$5.265

-0.225 (-4.27%)終値時点

Loading chart…
High
5.500
Open
5.500
VWAP
5.34
Vol
609.25K
Mkt Cap
15.23M
Low
5.260
Amount
3.25M
EV/EBITDA, TTM
0.00

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

unicycive.com

AI analysis of Unicycive Therapeutics Inc (UNCY)

hold

Unicycive Therapeutics is currently not a strong buy due to recent FDA setbacks and price volatility. The stock is priced at $5.265, with an RSI of 39.161 indicating potential oversold conditions. However, the company has faced significant challenges, including a 37% drop in stock price after receiving a Complete Response Letter from the FDA, which highlights ongoing manufacturing issues. The forward P/E ratio is 3.4447, suggesting potential undervaluation, but the risks are substantial given the recent regulatory hurdles and the company's negative net income of $12.823 million in Q1 2026.

バリュエーション指標

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY) is 3.44, compared to its 5-year average forward P/E of 0.20.

Forward P/E

Fair
5Y Average P/E
0.20
Current P/E
3.44
割高
6.86
割安
-6.46

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-6256.02
Current EV/EBITDA
0.00
割高
22678.07
割安
-35190.11

Forward P/S

Fair
5Y Average P/S
4.03
Current P/S
1.04
割高
15.55
割安
-7.50

Alphio AI Price Scenarios for UNCY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%UNCY

$5.26

シナリオ価格

B

Base

Base · 50%UNCY

$4.33

シナリオ価格

B

Bear

Bear · 25%UNCY

$3.97

シナリオ価格

Whales holding UNCY

L

Logos Global Management, L.P.

+ HoldingUNCY

+17.53%

3M Return

イベントタイムライン

2026-08-12 (ET)

08:00:00

Unicycive CEO Says OLC Application Progressing Well

2026-06-30 (ET)

09:00:00

Markets End Cautiously, Semiconductor Stocks Drive Gains

07:30:00

Unicycive Receives Complete Response Letter from FDA

2026-06-26 (ET)

13:00:00

Unicycive Resubmits Drug Application, Price Target $22

2026-06-05 (ET)

16:20:00

Unicycive Therapeutics Files $150M Mixed Securities Shelf

ニュース

UNCY FAQ — answered by Alphio AI

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Unicycive Therapeutics is currently not a strong buy due to recent FDA setbacks and price volatility. The stock is priced at $5.265, with an RSI of 39.161 indicating potential oversold conditions. However, the company has faced significant challenges, including a 37% drop in stock price after receiving a Complete Response Letter from the FDA, which highlights ongoing manufacturing issues. The forward P/E ratio is 3.4447, suggesting potential undervaluation, but the risks are substantial given the recent regulatory hurdles and the company's negative net income of $12.823 million in Q1 2026.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める